GUANGZHOU PHAR<00874> - Results Announcement

Guangzhou Pharmaceutical Company Limited announced on 12/08/2005:
(stock code: 00874 )
Year end date: 31/12/2005
Currency: RMB
Auditors' Report: N/A
Interim report reviewed by: Audit Committee

                                                        (Unaudited )
                                     (Unaudited )       Last
                                     Current            Corresponding
                                     Period             Period
                                     from 01/01/2005    from 01/01/2004
                                     to 30/06/2005      to 30/06/2004
                               Note  ('000      )       ('000      )
Turnover                           : 4,596,172          3,990,729         
Profit/(Loss) from Operations      : 216,239            111,291           
Finance cost                       : (30,216)           (22,482)          
Share of Profit/(Loss) of 
  Associates                       : (416)              (239)             
Share of Profit/(Loss) of
  Jointly Controlled Entities      : N/A                N/A               
Profit/(Loss) after Tax & MI       : 122,956            34,076            
% Change over Last Period          : +261      %
EPS/(LPS)-Basic (in dollars)       : 0.152              0.042             
         -Diluted (in dollars)     : N/A                N/A               
Extraordinary (ETD) Gain/(Loss)    : N/A                N/A               
Profit/(Loss) after ETD Items      : 122,956            34,076            
Interim Dividend                   : Nil                Nil
  per Share                                              
(Specify if with other             : N/A                N/A
  options)                                               
                                                         
B/C Dates for 
  Interim Dividend                 : N/A   
Payable Date                       : N/A
B/C Dates for (-)            
  General Meeting                  : N/A   
Other Distribution for             : N/A
  Current Period                     
                                     
B/C Dates for Other 
  Distribution                     : N/A   

Remarks:

The Group adopted the proportionate consolidation under HKAS 31 "Interest 
in Joint Ventures" to account for its interests in jointly controlled 
entities. In prior years, the Group's interests in jointly controlled 
entities were accounted for by the equity method.